S.Africa to analyse J&J vaccines made at U.S. plant halted over error
Africa
By
Reuters
| Jun 12, 2021
South African health inspectors will carry out further checks on a batch of Johnson & Johnson (JNJ.N) COVID-19 vaccines following a contamination error earlier this year at the U.S. plant where the doses were produced, the health ministry said.
As fears of a third COVID-19 wave grow in the hard-hit country, the ministry said late on Friday that officials from the health products regulator would assess the vaccines to ensure they are suitable for use.
"There is now a real possibility that they may not be, however, this is for the regulator to rule on," a ministry statement said.
The ministry said 300,000 J&J doses had been cleared for export to South Africa and that the U.S. Food and Drug Administration (FDA) had approved an extension of the expiry date, saying the vaccine can be stored at 2-8 degrees Celsius for 4.5 months instead of three.
READ MORE
Expert: The shilling has regained value, but don't expect it to last
Unearthing the artifacts of WWII: A journey through Matuu and beyond
Roam, County Bus Service partner to deploy 200 electric buses
Budget cuts loom for Parliament thanks to Sh9.6b Bunge Towers
Private sector partnerships important to catalysing sports
Tax stand-off as boda boda riders defy county call to pay
Islamic banking gets traction in Africa as Salaam Bank feted
Data privacy major challenge for Kenya's digital space, report
Angola ICT Minister: Invest in space industry to ensure a connected, peaceful Africa
"The FDA is still evaluating some batches and we will await those outcomes, in the hopes that this will make more doses of Johnson & Johnson available to the international community, including South Africa," the ministry added.
South Africa launched phase two of its vaccine rollout in May, aiming to inoculate five million people aged over 60 by the end of June. read more
Manufacturing at the Baltimore plant owned by Emergent Biosolutions Inc (EBS.N) was halted in April after the discovery that ingredients from AstraZeneca's (AZN.L) COVID-19 vaccine, also being produced at the plant at the time, had contaminated a batch of J&J's vaccine. read more
An inspection by the FDA also turned up a long list of sanitary problems and bad manufacturing practices at the Emergent plant.
- Expert: The shilling has regained value, but don't expect it to last
- Budget cuts loom for Parliament thanks to Sh9.6b Bunge Towers
- Lenders raise interest on loans despite CBK holding key rate